Mizuho Initiates Coverage On Harmony Biosciences with Buy Rating, Announces Price Target of $64

Mizuho analyst Graig Suvannavejh initiates coverage on Harmony Biosciences (NASDAQ:HRMY) with a Buy rating and announces Price Target of $64.

Mizuho analyst Graig Suvannavejh initiates coverage on Harmony Biosciences (NASDAQ:HRMY) with a Buy rating and announces Price Target of $64.

Total
0
Shares
Related Posts
Read More

5 Value Stocks In The Utilities Sector

What are Value Stocks? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.

KEN